- Browse by Author
Browsing by Author "Fox-Fuller, Joshua T."
Now showing 1 - 1 of 1
Results Per Page
Sort Options
Item Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease(Wiley, 2023) Aguillon, David; Langella, Stephanie; Chen, Yinghua; Sanchez, Justin; Su, Yi; Vila-Castelar, Clara; Vasquez, Daniel; Zetterberg, Henrik; Hansson, Oskar; Dage, Jeffrey L.; Janelidze, Shorena; Chen, Kewei; Fox-Fuller, Joshua T.; Aduen, Paula; Martinez, Jairo E.; Garcia, Gloria; Baena, Ana; Guzman, Claudia; Johnson, Keith; Sperling, Reisa A.; Blennow, Kaj; Reiman, Eric M.; Lopera, Francisco; Quiroz, Yakeel T.; Neurology, School of MedicineIntroduction: Plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of Alzheimer's disease (AD). We investigated whether plasma p-tau217 predicts subsequent cognition and positron emission tomography (PET) markers of pathology in autosomal dominant AD. Methods: We analyzed baseline levels of plasma p-tau217 and its associations with amyloid PET, tau PET, and word list delayed recall measured 7.61 years later in non-demented age- and education-matched presenilin-1 E280A carriers (n = 24) and non-carrier (n = 20) family members. Results: Carriers had higher plasma p-tau217 levels than non-carriers. Baseline plasma p-tau217 was associated with subsequent amyloid and tau PET pathology levels and cognitive function. Discussion: Our findings suggest that plasma p-tau217 predicts subsequent brain pathological burden and memory performance in presenilin-1 E280A carriers. These results provide support for plasma p-tau217 as a minimally invasive diagnostic and prognostic biomarker for AD, with potential utility in clinical practice and trials. Highlights: Non-demented presenilin-1 E280A carriers have higher plasma tau phosphorylated at threonine 217 (p-tau217) than do age-matched non-carriers. Higher baseline p-tau217 is associated with greater future amyloid positron emission tomography (PET) pathology burden. Higher baseline p-tau217 is associated with greater future tau PET pathology burden. Higher baseline p-tau217 is associated with worse future memory performance.